Spots Global Cancer Trial Database for Study of Metastatic Ocular Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Metastatic Ocular Melanoma
Official Title: Randomized Phase II Study to Compare a Combination Therapy With Gemcitabine and Treosulfan Versus a Monotherapy as First-Line Chemotherapy for Patients With Metastatic Ocular Melanoma
Study ID: NCT00168870
Conditions
Study Description
Brief Summary: This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma.
Detailed Description: Treatment of patients with metastatic ocular melanoma with combination chemotherapy Gemcitabine and Treosulfan versus monotherapy with Treosulfan as first-line chemotherapy.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hematology & Oncology Charité CBF Berlin, Berlin, , Germany
Contact Details
Name: Ulrich Keilholz, MD
Affiliation: Charité Campus Benjamin Franklin Berlin
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
